Sotrastaurin

For research use only. Not for use in humans.

目录号:S2791 别名: AEB071

Sotrastaurin Chemical Structure

CAS No. 425637-18-9

Sotrastaurin (AEB071) 是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 1414.55 现货
RMB 5468.97 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Sotrastaurin发表文献42篇:

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Sotrastaurin (AEB071) 是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。
特性 同以往的PKC抑制剂不同,AEB071并不会在激活诱导的细胞死亡模型中增强鼠T细胞原幼细胞的凋亡。
靶点
PKCθ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCα [1]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCδ [1]
(Cell-free assay)
0.22 nM(Ki) 0.64 nM(Ki) 0.95 nM(Ki) 1.8 nM(Ki) 2.1 nM(Ki)
体外研究

在人和鼠的早期T细胞中,毫微摩尔级浓度的AEB071 (< 10μM)则能有效消除早期T细胞激活的信号如白介素-2分泌物和CD25表达。在没发生非特异性抗增殖的效应的细胞中,AEB071 (200 nM)能抑制CD3/CD28抗体和同种抗原诱导的T瞎报增殖反应。AEB071(<3 μM)可以显著抑制淋巴细胞功能相关抗原1介导的T细胞的粘附作用。[1] AEB071(< 20 μM)特异性地降低CD79突变体ABC DLBCL细胞系的增殖,随之能减少NF-κB信号活性。3 μM 浓度的AEB071可诱导CD79突变细胞在G1阻断和/或细胞坏死。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cell MV3GeY5kfGmxbjDBd5NigQ>? M2K1blExOCCwTR?= NVHpZ4o{OyCq MmjtSG1UVw>? NI\KdpRqdmirYnn0d{BzWk6DIIP5cpRp\XOrcx?= M3mzSlI2PjlzMUW4
HUVECs  M2C5cmZ2dmO2aX;uJGF{e2G7 M1vqZVUxOG6P MmD1NUBp NUTOXYZwWmWmdXPld{BFXFhvVILp[4dmemWmIFXu[I91cGWuaXHsJGR6e2[3bnP0bY9v NFS5PXIzPTZ|NEWzPC=>
A549 MUjGeY5kfGmxbjDBd5NigQ>? M3SzRlAvOcLizszN NIjmXpQzPCCq NXfLZnEx\GWlcnXhd4V{KHSqZTDy[YxifGm4ZTDQT2Mu|rFibHX2[Ywhd25iY3XscEBu\W2kcnHu[UBkd3S{ZXH0[YQhSVNvSW[= M4e0b|I2OjF6MU[x
A549 MknLSpVv[3Srb36gRZN{[Xl? NXH2dphyOC5zwrFOwG0> NHfF[mUzPCCq NWnhWXpZemWmdXPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gUW1RNTJuIF3NVE06KGGwZDDpcpRm\3KrbjFOtlE> NHjjTZozPTJzOEG2NS=>
A549 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuwMlHDqM7:TR?= MmXENlQhcA>? MWjlcohidmOnczDndo94fGhiaX7obYJqfGmxbjDjc5Rz\WG2ZXSge4l1cCCDUz3JWi=> NYPSfXBtOjV{MUixOlE>
Mel202 NEjTW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXpNE42KM7:TR?= Ml3TN{Bp NF7GSXFFVVOR MXTlcohidmOnczDJVk1qdmS3Y3XkJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fS=> NYfMeI1kOjR3OUWzPFU>
92.1 NFT3NYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OxOFAvPSEQvF2= MknYN{Bp MVHEUXNQ MorW[Y5p[W6lZYOgTXIucW6mdXPl[EBz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJk> MoH2NlQ2QTV|OEW=
OCM3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;YNE42KM7:TR?= MXKzJIg> NFfhXXFFVVOR MVflcohidmOnczDJVk1qdmS3Y3XkJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fS=> M33o[VI1PTl3M{i1
Mel202 NEnFRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf5d3RJOC53IN88US=> M3nzWFMhcA>? NVvPNVVZTE2VTx?= MkfTbY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? MkL2NlQ2QTV|OEW=
92.1 NUHFTG4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGwMlUh|ryP MlzTN{Bp NV25Wpp6TE2VTx?= MnLibY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? NFXjV2gzPDV7NUO4OS=>
OCM3 NHjYNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\wNE42KM7:TR?= MVezJIg> M2XJfmROW09? M2nlcYlv[3KnYYPld{BKWi2rbnT1Z4VlKGOnbHygZ5lkdGViYYLy[ZN1yqB? NWLifpNyOjR3OUWzPFU>
Jeko-1 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;LSJFMOC12IN88US=> MnXVSG1UVw>? NE\MWmNqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1O1eVI1OzZ{OUO1
Mino NX;DVWc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2N5cxNTRizszN M4Xnd2ROW09? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MYSyOFM3Ojl|NR?=
Rec-1 M3fYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQemQ3OC12IN88US=> M{jLUGROW09? NVvEd2Y2cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{DBUVI1OzZ{OUO1
SP49 M2\VWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXBNE01KM7:TR?= M13Nb2ROW09? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXzCb|dvOjR|NkK5N|U>
Jeko-1 M1j2OGZ2dmO2aX;uJGF{e2G7 NXvGUVhUOi53IN88UeKh NIW1TXcyOiCq NVrFe2tnTE2VTx?= MkLx[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| NHXreGYzPDN4MkmzOS=>
Mino NYHidml7TnWwY4Tpc44hSXO|YYm= Moq0Nk42KM7:TdMg NV\3eJlkOTJiaB?= MV\EUXNQ NV\hfpZ2\G:5boLl[5Vt[XSnczDOSk3PwkJidHHy[4V1KGenbnXz MVKyOFM3Ojl|NR?=
Rec-1 MXTGeY5kfGmxbjDBd5NigQ>? MYiyMlUh|ryPwrC= NVPiNJlGOTJiaB?= NILRUGFFVVOR Mley[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| MmP4NlQ{PjJ7M{W=
SP49 MVLGeY5kfGmxbjDBd5NigQ>? MWWyMlUh|ryPwrC= MUmxNkBp MXzEUXNQ NVLibIE5\G:5boLl[5Vt[XSnczDOSk3PwkJidHHy[4V1KGenbnXz NVrRdm1NOjR|NkK5N|U>
CD3+ T  M{PiRmZ2dmO2aX;uJGF{e2G7 NEjHeosxNTVyMDDuUS=> NWXNXlZnOSCq MVLpcohq[mm2czDOSk3PwkJicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NYHDbZBqOjN3N{OyPFM>
Mel202 NHi3V3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5NE02KM7:TR?= NEnMZW84OiCq Mn6ySG1UVw>? MYnpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MV2yNlY2Ozl4OB?=
Omm1.3 NFrMOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMVUh|ryP M1\3WVczKGh? NYPNV2Z3TE2VTx?= Mn\MbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXLHZZU1OjJ4NUO5Olg>
92.1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOzNE02KM7:TR?= NISxcJc4OiCq NFXFSJVFVVOR MojabY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mkf4NlI3PTN7Nki=
Mel202 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL5eHRUPSEQvF2= MYiyOEBp Mlm3SG1UVw>? MnPIbY5lfWOnczDHNUBienKnc4VCpC=> M{LNTVIzPjV|OU[4
Omm1.3 NFSyOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLkW402KM7:TR?= MWeyOEBp NUfvNFlzTE2VTx?= MoHDbY5lfWOnczDHNUBienKnc4VCpC=> MUOyNlY2Ozl4OB?=
92.1 NEf2bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\rOUDPxE1? NEDPSYQzPCCq MoPZSG1UVw>? MWHpcoR2[2W|IFexJIFzemW|dNMg MWKyNlY2Ozl4OB?=
Mel202 MXTBdI9xfG:|aYOgRZN{[Xl? NIriSJY2KM7:TR?= NEWyPWg4OiCq MlnOSG1UVw>? NUH6U3Z[cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> M3T5OlIzPjV|OU[4
Omm1.3 Mn;MRZBweHSxc3nzJGF{e2G7 NXHLUIZyPSEQvF2= NFTwfYU4OiCq NYjrRZRTTE2VTx?= Mk[3bY5lfWOnczDhdI9xfG:|aYO= NYrybYlNOjJ4NUO5Olg>
92.1 Ml3ZRZBweHSxc3nzJGF{e2G7 MnqxOUDPxE1? MVO3NkBp M2fIPWROW09? NHW5NmpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\jZY51dHl? MmGxNlI3PTN7Nki=
Mel202 NGj5fGRHfW6ldHnvckBCe3OjeR?= M2faVlUh|ryP MWqyOEBp MYfpcohq[mm2czDlfJBz\XO|aX;uJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiUFvDJIl{d2[xcn3z NXu2Olh[OjJ4NUO5Olg>
Omm1.3 M3LQPWZ2dmO2aX;uJGF{e2G7 MVG1JO69VQ>? M1HUNVI1KGh? MV3pcohq[mm2czDlfJBz\XO|aX;uJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiUFvDJIl{d2[xcn3z M1zwd|IzPjV|OU[4
92.1 NEjJO29HfW6ldHnvckBCe3OjeR?= NUj1coJQPSEQvF2= MoLxNlQhcA>? NUDpR4JLcW6qaXLpeJMh\XiycnXzd4lwdiCjbnSgdIhwe3Cqb4L5cIF1cW:wIH;mJHBMSyCrc3;mc5Juew>? NUTzS2VoOjJ4NUO5Olg>
HBL1 NYnZXmR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi1NIIxNjF4LUKwJO69VQ>? MU[1JIQ> NXf4bG9PUUN3ME2wMlUh|ryP MnfJNlE{OjR7MkC=
TMD8 M2LTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOwMlE3NTJyIN88US=> NWOwN4hQPSCm NV76V49qUUN3ME2wMlIh|ryP M2O5fVIyOzJ2OUKw
OCI-Ly10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLUcm9TOC5zNj2yNEDPxE1? MYG1JIQ> MlK3TWM2OD1zLkOg{txO NWKzU2pYOjF|MkS5NlA>
U2932 NV\NbYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MViwMlE3NTJyIN88US=> M{TRR|Uh\A>? NYrVTYtOUUN3ME2xNEDPxE1? M1vPSVIyOzJ2OUKw
OCI-Ly3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[zdXprOC5zNj2yNEDPxE1? MWG1JIQ> NHKzR49KSzVy78{eNlAh|ryP MYKyNVMzPDl{MB?=
SuDHL2 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf6NE4yPi1{MDFOwG0> M3y3OlUh\A>? MYnJR|Ux97zgMkCg{txO NYq4d2ZXOjF|MkS5NlA>
SuDHL4 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDQR4oxNjF4LUKwJO69VQ>? NF7hfWc2KGR? NXqxdpczUUN3MP-8olIxKM7:TR?= MnfaNlE{OjR7MkC=
DB NHvJ[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzWO2QxNjF4LUKwJO69VQ>? MnrmOUBl MX3JR|Ux97zgMkCg{txO NYPmcWJVOjF|MkS5NlA>
Jurkat IL-2 M1vlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jSRWlEPTB;Nj63NUDDuSB|Lke2JO69VQ>? MVKxPVk1ODJ3OR?=
PBMC IL-2 MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\R[mlEPTB;ND64OEDDuSBzLkewJEDPxE1? MoiyNVk6PDB{NUm=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pPKCδ/θ / phosphorylated MARCKS / p53 / MDM2 / PUMA / p21; 

PubMed: 29593251     


Cell lines OMM2.3, OMM2.5 and OMM1 were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM Nutlin-3 and 1 µM Sotrastaurin, and cell lines MEL202, MEL270 and MM66 with 2䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ€𢡄뙤ෆ€䀷痗뙤ෆ౴뙤ෆ㵶痗뙤ෆ뺖᎒泌Itemセ᎒Count﫨呂뚔ෆ猴፲뙤ෆ፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄堚Ѽ齃礤v�堞ﻮ᎒猢Wセ᎒䨼Ą鹿齃

Cyclin D1 / p27(Kip1) ; 

PubMed: 22653968     


AEB071 selectively increased p27 and decreased cyclin D1 expression in GNAQ mutant UM cells. Cells were treated with 0, 2, or 5 μM AEB071 for 72 hours and analyzed by immunoblot. WT = GNAQ wild type; MT = GNAQ mutation.

Bcl-xl / XIAP / Survivin ; 

PubMed: 22653968     


AEB071 decreased the expression of antiapoptotic proteins Bcl-xL, XIAP, and survivin in GNAQ mutated cells. WT = GNAQ wild type; MT = GNAQ mutation.

PKCα / PKCδ / PKCβ / PKCε / PKCθ ; 

PubMed: 22653968     


AEB071 inhibited PKC expression in UM cells. Cells were treated with 5 μM AEB071 for 24 hours in the presence of 10% FBS and subjected to immunoblot analysis. PKCδ, ε and θ levels in AEB treated cells relative to control (DMSO treated) cells are also show䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨Ղà㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ猴፲사Ղ፲씢痗猸፲髸莤䥷堙᎒

p-Marcks / p-ERK / p-AKT / p-S6 / Marcks / ERK / AKT / S6; 

PubMed: 22653968     


AEB071 inhibits PKC and mTOR pathways but not AKT. Western Blot of MARCKS, ERK, ribosomal S6 and AKT phosphorylation following drug treatments for 24 hrs. α-Tubulin was used as a loading control.

29593251 22653968
Growth inhibition assay
Cell viability ; 

PubMed: 22653968     


AEB071 selectively reduced viability of UM cells harboring GNAQ mutations. Cells were treated with varying amount of AEB071 for 72 hours. Data are presented as mean±SD of 4 or 5 independent experiments. NM = normal melanocytes; WT = GNAQ wild type; MT = G䲧疝Ỵ疞㧀疜膉

22653968
体内研究 AEB071(80 mg/kg) 可以在体内显著抑制SCID的皮下TMD8移植模型肿瘤的生长。[2] 每日两次口服10 mg/kg 和30 mg/kg AEB071,能延长心脏移植的大鼠的存活率,这种作用是剂量依赖抑制免疫力的效应。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[3]
- 合并
  • Animal Models: 雄性 Wistar/F大鼠
  • Dosages: 10 mg/kg 和 30 mg/kg
  • Administration: 口服一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.41 mM)
Ethanol 2 mg/mL (4.56 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 438.48
化学式

C25H22N6O2

CAS号 425637-18-9
储存条件 粉状
溶于溶剂
别名 AEB071

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02273219 Unknown status Drug: AEB071|Drug: BYL719 Uveal Melanoma Richard D. Carvajal|Columbia University November 2014 Phase 1
NCT01801358 Terminated Drug: AEB071|Drug: MEK162 Uveal Melanoma Array BioPharma August 2013 Phase 1|Phase 2
NCT01430416 Completed Drug: AEB071 Uveal Melanoma Novartis Pharmaceuticals|Novartis December 20 2011 Phase 1
NCT01402440 Terminated Drug: AEB071 Diffuse Large B-Cell Lymphoma Novartis Pharmaceuticals|Novartis November 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you give me the information about how to prepare Sotrastaurin for oral administration in mice?

  • 回答:

    S2791 Sotrastaurin can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution which can be used for injection, and in 2% DMSO/corn oil at 10 mg/ml as a suspension for oral administration.

PKC Signaling Pathway Map

PKC Inhibitors with Unique Features

相关PKC产品

Tags: 购买Sotrastaurin | Sotrastaurin供应商 | 采购Sotrastaurin | Sotrastaurin价格 | Sotrastaurin生产 | 订购Sotrastaurin | Sotrastaurin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID